Takeda Pharmaceutical Company Limited
TAK
$15.16
$0.130.87%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.50B | 7.91B | 7.75B | 7.08B | 7.53B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50B | 7.91B | 7.75B | 7.08B | 7.53B |
| Cost of Revenue | 2.73B | 2.65B | 2.48B | 2.61B | 2.57B |
| Gross Profit | 4.77B | 5.26B | 5.27B | 4.47B | 4.96B |
| SG&A Expenses | 1.77B | 1.80B | 1.73B | 1.92B | 1.81B |
| Depreciation & Amortization | 879.81M | 946.30M | 877.86M | 901.56M | 906.40M |
| Other Operating Expenses | 958.94M | -298.11M | 342.49M | -9.65M | 494.91M |
| Total Operating Expenses | 7.46B | 6.29B | 6.52B | 6.73B | 7.05B |
| Operating Income | 39.68M | 1.63B | 1.23B | 346.00M | 474.01M |
| Income Before Tax | 173.16M | 803.13M | 876.40M | -320.14M | 415.02M |
| Income Tax Expenses | 16.87M | 183.44M | 264.99M | -299.97M | -301.46M |
| Earnings from Continuing Operations | 156.29M | 619.69M | 611.41M | -20.17M | 716.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -301.60K | -410.40K | -327.20K | -161.70K | -237.10K |
| Net Income | 155.99M | 619.28M | 611.08M | -20.33M | 716.24M |
| EBIT | 39.68M | 1.63B | 1.23B | 346.00M | 474.01M |
| EBITDA | 1.27B | 2.92B | 2.47B | 1.04B | 1.74B |
| EPS Basic | 0.10 | 0.39 | 0.39 | -0.01 | 0.46 |
| Normalized Basic EPS | -0.09 | 0.52 | 0.42 | 0.07 | 0.07 |
| EPS Diluted | 0.10 | 0.38 | 0.38 | -0.01 | 0.46 |
| Normalized Diluted EPS | -0.09 | 0.51 | 0.41 | 0.07 | 0.07 |
| Average Basic Shares Outstanding | 1.59B | 1.58B | 1.57B | 1.57B | 1.57B |
| Average Diluted Shares Outstanding | 1.59B | 1.61B | 1.59B | 1.57B | 1.57B |
| Dividend Per Share | 0.00 | 0.66 | -- | 0.63 | 0.00 |
| Payout Ratio | 611.42% | 9.99% | 145.00% | -302.39% | 130.77% |